Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
Moritz J. Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth Coleman, Julian L. Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J.J.J. Miller, Joanne E. Milton, Shveta Monga, Ferenc E. Mózes, Areesha Nazeer, Betty Raman, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer
Circulation 2023;147:1654-1669. Published:30-May-2023. Epub:18-Apr-2023.
PMID:37070436.
doi:10.1161/CIRCULATIONAHA.122.062021
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod and Stefan Neubauer
ESC Heart Failure 2021;8:2580-2590. Published:Aug-2021. Epub:06-May-2021.
PMID:33960149.
doi:10.1002/ehf2.13406
